Mivagyn vaginal tablets clinical study on vaginal pH and flora Vaginal wellbeing depends on a delicate balance between bacterial flora, mucosal hydration, and pH. A lactobacilli-dominated flora contributes to lactic acid production and helps maintain an acidic vaginal environment that is unfavorable to the proliferation of opportunistic microorganisms. When this balance is altered, symptoms such…
Vaginal medical device is effective against infections and vaginal dryness Vulvovaginal infections caused by Candida albicans are among the leading causes of intimate discomfort in women, with recurring symptoms such as itching, burning, leucorrhoea, and pain during intercourse. They affect women of all ages and may occur even in the absence of evident risk factors.…
Gruppo FarmaImpresa at the Top of European Quality: Maximum Safety for Gynecologic Well-Being The EU Regulation 2017/745 (MDR) is Europe’s most stringent framework for manufacturing and marketing medical devices. It raises the bar on safety, quality, and traceability, introducing far stricter requirements than previous directives. For Gruppo FarmaImpresa, obtaining MDR certification for the Class IIb…
MDD Certified Vaginal Tablets for Intimate Health The Medical Device Regulation (MDR), in effect since May 2017 and fully applicable from May 2021, regulates medical devices in Europe. Thanks to deadline extensions, devices compliant with the MDD Directive can continue to be marketed until December 31, 2027, for Class III and implantable Class IIb devices,…
MDD Certification for Our Vaginal Ovules: A New Milestone for Intimate Health The MDR Regulation, in force since May 2017 and applicable from May 2021, governs European medical devices. Deadline extensions allow medical devices compliant with the Medical Device Directive (MDD) to be marketed until December 31, 2027, for Class III and implantable Class IIb…